Arnold E. Feldman, M.D.; Decision and Order, 55635-55639 [2017-25287]
Download as PDF
Federal Register / Vol. 82, No. 224 / Wednesday, November 22, 2017 / Notices
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. 17–34]
asabaliauskas on DSKBBXCHB2PROD with NOTICES
Arnold E. Feldman, M.D.; Decision and
Order
On May 24, 2017, the Assistant
Administrator, Diversion Control
Division, issued an Order to Show
Cause to Arnold E. Feldman, M.D.
(Respondent), of Natchez, Mississippi.
The Show Cause Order proposed the
revocation of Respondent’s DEA
Certificate of Registration No.
AF2451261, on the ground that he
‘‘do[es] not have authority to handle
controlled substances in the State of
Mississippi, the [S]tate in which [he is]
registered with . . . DEA.’’ Show Cause
Order, at 1.
As to the jurisdictional basis for the
proceeding, the Show Cause Order
alleged that Respondent is ‘‘registered as
a practitioner in [s]chedules II–V
pursuant to [Registration No.]
AF2451261 with a registered address at
114 Jefferson Davis [Blvd.], Natchez,
Mississippi.’’ Id. The Order also alleged
that this registration does not expire
until ‘‘September 30, 2018.’’ Id.
As to the substantive ground for the
proceeding, the Show Cause Order
alleged that Respondent’s ‘‘[a]uthority to
prescribe and administer controlled
substances in the State of Mississippi
was suspended effective March 16,
2017.’’ Id. The Order then asserted that
as a consequence of Respondent’s ‘‘lack
of authority to handle controlled
substances in the State of Mississippi,’’
his registration is subject to revocation.
Id.
The Show Cause Order notified
Respondent of his right to request a
hearing on the allegation or to submit a
written statement while waiving his
right to a hearing and the procedure for
electing either option. Id. at 2 (citing 21
CFR 1301.43). In addition, the Order
notified Respondent of his right to
submit a corrective action plan pursuant
to 21 U.S.C. 824(c)(2)(C). Id. at 2–3.
On June 15, 2017, Respondent,
through his counsel, requested a hearing
on the allegation. Letter from
Respondent’s Counsel to Hearing Clerk,
Office of Administrative Law Judges
(June 15, 2017). The same day, the
matter was assigned to Administrative
Law Judge Charles Wm. Dorman
(hereinafter, ALJ), who issued an order
(also on June 15) directing the
Government to file evidence supporting
the allegation by June 28, 2017 at 2 p.m.,
as well any motion for summary
disposition. Briefing Schedule For Lack
Of State Authority Allegations, at 1. The
VerDate Sep<11>2014
18:57 Nov 21, 2017
Jkt 244001
ALJ’s order also provided that if the
Government moved for summary
disposition, Respondent’s opposition
was due by July 12, 2017 at 2 p.m. Id.
On June 20, 2017, the Government
filed its Motion for Summary
Disposition. As support for its motion,
the Government provided, inter alia: (1)
A copy of Respondent’s registration; (2)
the Determination of the Mississippi
State Board of Medical Licensure (Mar.
16, 2017) which ordered the suspension
of his medical license ‘‘to run
concurrently’’ with the suspension of
his Louisiana medical license that was
imposed by the Louisiana Board of
Medical Examiners’ Order of August 15,
2016; 1 and (3) a Declaration of a
Diversion Investigator. Mot. for Summ.
Disp., Appendices A, B, C. In its motion,
the Government argued that it was
undisputed that Respondent’s
Mississippi medical license is
suspended and that because
‘‘Respondent no longer meets the
statutory definition of a practitioner’’
and ‘‘possession of authority to dispense
controlled substances under the laws of
the State in which a practitioner engages
in professional practice is a
fundamental condition for both
obtaining and maintaining a
practitioner’s registration,’’ the
revocation of Respondent’s registration
for his Mississippi office is warranted.
Mot. for Summ. Disp., at 3–4.
On July 10, 2017, Respondent filed
his Reply to the Government’s Motion.
Therein, ‘‘Respondent acknowledge[d]
that his license to practice medicine in
. . . Mississippi has been suspended in
accordance with the . . . Mississippi
State Board of Medical Licensure’s
Order.’’ Resp. Reply, at 1. Respondent
contended, however, ‘‘that there are
material questions of fact and law that
require resolution in a plenary,
evidentiary proceeding.’’ Id.
According to Respondent, these issues
are that he possesses ‘‘an active and
unrestricted license to practice
medicine in’’ Alabama and ‘‘a full and
unrestricted Alabama Controlled
Substance Certificate.’’ Id. at 2.
Respondent argued that ‘‘none of the
cases cited by the Government’’ address
1 The Government also included various other
documents from the Mississippi Board proceeding,
including an Order of Continuance, an Order of
Temporary Action Pending Hearing, a Summons
issued to Respondent, an Affidavit of a Board
Investigator, and a copy of the Louisiana Board’s
Decision and Order which was an exhibit in the
Mississippi Board proceeding. See generally Mot.
for Summ. Disp., at Appendix B. Based on the
suspension of his Louisiana medical license, on
August 14, 2017, the former Acting Administration
revoked Respondent’s DEA registration for his
practice in Baton Rouge, Louisiana. See Arnold E.
Feldman, 82 FR 39614, 39618 (2017).
PO 00000
Frm 00083
Fmt 4703
Sfmt 4703
55635
the situation ‘‘where a physician has
lost authority to practice in one state,
while retaining unrestricted authority in
another.’’ Id. at 3. He also argued that
the Agency’s longstanding rule that a
practitioner must possess authority
under the laws of the State in which he
engages in professional practice ‘‘is
based on the indiscriminate
intermingling of’’ 21 U.S.C. 823 and
824, ‘‘each of which deals with different
aspects of the control and enforcement
authority to dispense controlled
substances.’’ Id. He further contended
that while section 823 mandates that the
Attorney General ‘‘register the
applicant’’ if he ‘‘is authorized to
dispense controlled substances under
the laws of the State in which he
practices,’’ ‘‘[t]he term ‘practitioner’
does not appear in’’ section 824 and the
latter provision ‘‘does not speak to a
physician’s authorization to practice or
dispense under the laws of the state in
which the registrant practices.’’ Id. at 4.
In Respondent’s view, section 824
authorizes revocation ‘‘only if the
registrant is no longer authorized by
State law to engage in the dispensing of
controlled substances [under] any state
law.’’ Id. at 5. He also maintained that
‘‘[t]he fact that Congress employed the
term ‘practitioner’ in’’ section 823(f) but
not in section 824 ‘‘is a clear indication
that it did not intend to authorize
revocation or suspension of a
[registration] where a registrant has
continued to maintain authority to
practice and dispense under the laws of
any state.’’ Id.; see also id. at 5 & n.14
(‘‘Where Congress includes particular
language in one section of a statute but
omits it in another . . . it is generally
presumed that Congress acts
intentionally and purposely in the
disparate inclusion or exclusion.’’)
(quoting Keene Corp. v United States,
508 U.S. 200, 208 (1993) (other citation
omitted)).
Finally, Respondent contended that
‘‘[t]he Government, and the cases cited
by it, indiscriminately (and erroneously)
intermingle’’ sections 823 and 824, and
this intermingling along with ‘‘its
misinterpretation of 21 U.S.C. 824(a)(3)
amount to a violation of [his]
constitutional right to travel.’’ Id. at 6–
7. He argued that ‘‘[t]heoretically, [he]
should be able to pack up and remove
himself and his practice from Louisiana
to . . . Alabama, where he is authorized
to practice medicine and dispense
controlled substances. But[] his
constitutional right to do so is impaired
by the Government’s misinterpretation
of its authority to revoke’’ his
registration. Id. at 7.
On July 25, 2017, the ALJ granted the
Government’s Motion. The ALJ found
E:\FR\FM\22NON1.SGM
22NON1
asabaliauskas on DSKBBXCHB2PROD with NOTICES
55636
Federal Register / Vol. 82, No. 224 / Wednesday, November 22, 2017 / Notices
that ‘‘Respondent conceded in his Reply
that his Mississippi medical license is
currently suspended’’ and that ‘‘it is
undisputed that . . . Respondent lacks
state authorization to handle controlled
substances in Mississippi, where [his
Registration] Number AF2451261[] is
registered.’’ ALJ’s Recommended
Decision (R.D.), at 6. Because
Respondent is registered in Mississippi,
the ALJ found it irrelevant that
Respondent holds a license to practice
medicine in Alabama. Id. at 4 (citing
cases). The ALJ noted that ‘‘both the
CSA’s ‘definition of the term
‘‘practitioner’’ and the registration
provision applicable to practitioners
make clear that a practitioner must be
currently authorized to dispense
controlled substances by the State in
which he practices in order to obtain
and maintain a registration,’’’ and that
the Agency’s interpretation has been
upheld by the Fourth Circuit. Id.
(quoting Rezik A. Saqer, 81 FR 22122,
22125 (2016) and citing Hooper v.
Holder, 481 Fed. App’x 826 (4th Cir.
2012)). The ALJ further reasoned that
‘‘Respondent’s analysis is counter to the
way the DEA has interpreted the CSA
for nearly forty years.’’ Id. at 5 (citing
Saqer, 81 FR at 22126 (citing Frederick
Marsh Blanton, 43 FR 27616 (1978))).
The ALJ also rejected Respondent’s
contention that the Agency’s
interpretation impairs his constitutional
right to travel. Id. at 5–6. The ALJ noted
that under DEA’s regulation, ‘‘ ‘[a]
separate registration is required for each
principal place of business.’ ’’ Id. at 5
(quoting 21 CFR 1301.12(a)). The ALJ
also noted that in 2006, the Agency
issued a final rule which ‘‘clarif[ied]
that a practitioner must obtain a
separate DEA registration for each
[S]tate in which he or she practices,’’
and that ‘‘ ‘[j]ust as a license to practice
medicine in one State does not
authorize a practitioner to practice in
any other State, a DEA registration
based on a particular State’s license
cannot authorize dispensing controlled
substances in another State.’ ’’ Id. at 6
(quoting Clarification of Registration
Requirements for Individual
Practitioners, 71 FR 69478, 69479 (2006)
and citing Joe W. Morgan, 78 FR 61961,
61965 n.13 (2013)). The ALJ thus
explained that ‘‘Respondent is able to
pack up and remove himself and his
practice from [Mississippi] to
Alabama—he just cannot dispense or
prescribe controlled substances there
unless he first obtains a separate DEA
registration for his Alabama location in
accordance with 21 CFR 1301.12(a).’’ Id.
The ALJ thus recommended that I
VerDate Sep<11>2014
18:57 Nov 21, 2017
Jkt 244001
revoke Respondent’s registration. Id. at
7.
Neither party filed Exceptions to the
ALJ’s Recommended Decision.
Thereafter, on August 22, 2017, the ALJ
forwarded the record to me for Final
Agency Action.2
Having considered the record, I reject
Respondent’s various contentions and
adopt the ALJ’s Recommended
Decision. I will therefore also adopt the
ALJ’s recommendation that I revoke
Respondent’s registration. I make the
following findings.
Findings of Fact
Respondent is the holder of DEA
Certificate of Registration No.
AF2451261, pursuant to which he is
authorized to dispense controlled
substances in schedules II through V as
a practitioner, at the registered address
of: Southwest MS Anesthesia PA, 114
Jefferson Davis Blvd., Natchez,
Mississippi. Mot. for Summ. Disp.,
Appendix A. This registration does not
expire until September 30, 2018. Id.
Respondent also holds a medical
license issued by the Mississippi State
Board of Medical Licensure. See Mot.
for Summ. Disp., Appendix B,
Determination and Order, at 2.
However, on March 16, 2017, the Board
issued a Determination and Order
which suspended his medical license
for a period ‘‘to run concurrently with’’
the suspension of his Louisiana medical
license, ‘‘that is, until October 14, 2018,
at which time [he] shall petition the
Board for removal of the suspension’’;
the Mississippi Board’s Order was
effective on April 17, 2017. Id. at 4.
Accordingly, I find that Respondent
currently lacks authority to dispense
controlled substances under the laws of
the State of Mississippi.
Discussion
Pursuant to 21 U.S.C. 824(a)(3), the
Attorney General is authorized to
suspend or revoke a registration issued
under section 823 of the Controlled
Substances Act (CSA), ‘‘upon a finding
that the registrant . . . has had his State
license . . . suspended [or] revoked
. . . by competent State authority and is
no longer authorized by State law to
engage in the . . . dispensing of
controlled substances.’’ With respect to
a practitioner, DEA has long held that
the possession of authority to dispense
controlled substances under the laws of
the State in which a practitioner engages
in professional practice is a
fundamental condition for obtaining
2 Subsequent to the ALJ’s issuance of his
Recommended Order, Respondent has not filed a
motion based on newly discovered evidence to the
effect that his state licensed has been restored.
PO 00000
Frm 00084
Fmt 4703
Sfmt 4703
and maintaining a practitioner’s
registration. See, e.g., James L. Hooper,
76 FR 71371 (2011), pet. for rev. denied,
481 Fed. Appx. 826 (4th Cir. 2012);
Frederick Marsh Blanton, 43 FR 27616
(1978).
Respondent acknowledges that the
Agency’s precedents ‘‘do indeed reveal
a consistent [and in his view] uncritical
repetition of th[is] claim, to an extent
. . . that the proposition has come to
attain near sacrosanct status.’’ Resp.
Reply, at 3. Before the ALJ, he
contended that the Agency’s rule ‘‘is
based on the indiscriminate
intermingling of’’ the registration
requirements of section 823 and the
suspension/revocation authority of
section 824. Id. He also argued that
because ‘‘the term ‘practitioner’ is
employed solely in 21 U.S.C. 823’’ and
‘‘does not appear in section 824’’ this
‘‘is a clear indication that [Congress] did
not intend to authorize an automatic,
summary revocation . . . where a
registrant has continued to maintain
authority to practice and dispense under
the laws of any state.’’ Id. at 4.
Respondent is mistaken. As the
Agency has repeatedly noted, the
Agency’s rule actually derives from the
text of section 802(21), which defines
the term ‘‘practitioner,’’ and section
823(f), which sets forth the requirements
for obtaining a practitioner’s
registration. Notably, in section 802(21),
Congress defined ‘‘the term
‘practitioner’ [to] mean[ ] a . . .
physician . . . or other person licensed,
registered or otherwise permitted, by
. . . the jurisdiction in which he
practices . . . to distribute, dispense,
[or] administer . . . a controlled
substance in the course of professional
practice.’’ 21 U.S.C. 802(21). The text of
this provision makes clear that a
physician is not a practitioner within
the meaning of the CSA if he is not
‘‘licensed, registered or otherwise
permitted, by the jurisdiction in which
he practices . . . to dispense [or]
administer . . . a controlled substance
in the course of professional practice.’’
Id.
To the same effect, Congress, in
setting the requirements for obtaining a
practitioner’s registration, directed that
‘‘[t]he Attorney General shall register
practitioners . . . if the applicant is
authorized to dispense . . . controlled
substances under the laws of the State
in which he practices.’’ 21 U.S.C. 823(f).
Thus, based on these provisions, the
Agency held nearly 40 years ago that
‘‘[s]tate authorization to dispense or
otherwise handle controlled substances
is a prerequisite to the issuance and
maintenance of a Federal controlled
substances registration.’’ Blanton, 43 FR
E:\FR\FM\22NON1.SGM
22NON1
Federal Register / Vol. 82, No. 224 / Wednesday, November 22, 2017 / Notices
asabaliauskas on DSKBBXCHB2PROD with NOTICES
at 27617 (revoking physician’s
registration based on one-year
suspension of his state license)
(emphasis added).
As the ALJ recognized, the CSA also
provides that ‘‘[a] separate registration
shall be required at each principal place
of business or professional practice
where the applicant . . . dispenses
controlled substances.’’ 21 U.S.C.
822(e).3 Based on this provision, the
Agency has further explained that,
because the issuance of a registration is
dependent on a practitioner having
authority to dispense controlled
substances under the laws of a
particular State, a registration issued for
a location in one State cannot authorize
the practitioner to engage in controlled
substance dispensing in another State.
See Clarification of Registration
Requirements for Individual
Practitioners, 71 FR 69478 (2006); 21
CFR 1301.12(a) & (b)(3). See also United
States v. Moore, 423 U.S. 122, 140–41
(1975) (‘‘Registration of physicians and
other practitioners is mandatory if the
applicant is authorized to dispense
drugs . . . under the law of the State in
which he practices. [21 U.S.C. ] Sec.
823(f). In the case of a physician, this
scheme contemplates that he is
authorized by the State to practice
medicine and to dispense drugs in
connection with his professional
practice.’’).4
Notably, while Respondent holds a
medical license in Alabama, the
registration at issue in this proceeding
authorizes him to dispense controlled
substances only in the State of
Mississippi. Moreover, the Show Cause
Order proposes only the revocation of
this registration.5 Because Congress has
clearly mandated that a practitioner
possess state authority in order to be
deemed a practitioner under the Act,
and Respondent is no longer authorized
to dispense controlled substances under
the laws of Mississippi, the State of the
registration at issue here, revocation of
this registration is the appropriate
sanction. See, e.g., Hooper, 76 FR at
3 See also 21 U.S.C. 822(b) (‘‘Persons registered by
the Attorney General . . . to . . . dispense
controlled substances . . . are authorized to possess
. . . or dispense such substances . . . to the extent
authorized by their registration and in conformity
with the other provisions of this subchapter.’’).
4 While the CSA was amended in 1984 to provide
the Agency with authority to deny a practitioner’s
registration on public interest grounds, the
requirement that a practitioner be ‘‘authorized to
dispense . . . controlled substances under the laws
of the State in which he practices,’’ 21 U.S.C. 823(f),
was unaltered by this legislation.
5 There is no evidence in the record as to whether
Respondent holds a DEA registration in Alabama.
Nor does this matter, because the Government
proposes only the revocation of his Mississippi
registration.
VerDate Sep<11>2014
18:57 Nov 21, 2017
Jkt 244001
71371–72; Sheran Arden Yeates, 71 FR
39130, 39131 (2006); Dominick A. Ricci,
58 FR 51104, 51105 (1993); Bobby
Watts, 53 FR 11919, 11920 (1988);
Blanton, 43 FR at 27616.
As noted above, Respondent contends
that Congress’ use of the word
‘‘registrant’’ rather the word
‘‘practitioner’’ in section 824 ‘‘is a clear
indication that it did not intend to
authorize an automatic revocation of a
[registration] where a registrant has
continued to maintain authority to
practice and dispense under the laws of
any state.’’ Resp. Reply, at 5. A
practitioner is, however, a particular
category of registrant and thus falls
within section 824(a). Given the
provisions of section 802(21) and 823(f),
it is not clear why Congress needed to
use the word ‘‘practitioner’’ in section
824(a) to authorize the Agency to
effectuate the policy expressed by
sections 802(21) and 823(f). Moreover,
Respondent ignores that there is a good
reason for why Congress used different
language in sections 823(f) and 824(a) to
describe the class of persons who are
subject to each provision, and this
reason provides no support for
Respondent’s contention.
Section 823(f) is specifically
applicable to those applicants seeking
registration as a practitioner, which is
just one of eight different categories of
registration under the CSA. See
generally 21 U.S.C. 823. By contrast,
section 824(a), which authorizes the
imposition of sanctions against a
registrant based on any one of five
findings, is applicable to all categories
of registrants under the CSA, including
Respondent. See, e.g., James L. Hooper,
76 FR 71371 (2011), pet. for rev. denied
Hooper v. Holder, 481 Fed. Appx. 826,
829 (4th Cir. 2012).
As explained above, the Agency’s rule
that revocation is warranted whenever a
practitioner is no longer authorized to
dispense controlled substances under
the laws of the State in which he
engages in professional practice is
derived from the specific provisions of
the Act which define the term
‘‘practitioner’’ and set forth the
registration requirements which are
specifically applicable to
practitioners.6 Hooper, 76 FR at 71371–
6 Section 824(a)(3) grants authority applicable to
all categories of DEA registrants (and not only
practitioners) as well as each of the enumerated
findings. As explained in Hooper, this general grant
of authority in imposing a sanction must be
reconciled with the CSA’s specific provisions
which mandate that a practitioner hold authority
under state law in order to obtain and maintain a
DEA registration. 76 FR, at 71371–72 (quoting
Gozlon-Peretz v. United States, 498 U.S. 395, 407
(1991) (‘‘A specific provision controls over one of
more general application.’’) and Bloate v. United
PO 00000
Frm 00085
Fmt 4703
Sfmt 4703
55637
72. Indeed, were I to adopt
Respondent’s view, he would be
allowed to maintain his registration
even though his lack of state authority
bars him from obtaining a registration in
Mississippi in the first place. 21 U.S.C.
823(f).
Moreover, under DEA regulations, a
practitioner’s registration is good for a
period of three years, after which a
practitioner must submit a renewal
application. Yet that renewal
application remains subject to section
823(f), which requires that ‘‘the
applicant is authorized to dispense . . .
controlled substances under the laws of
the State in which he practices.’’
Respondent’s view leads to the illogical
result that a practitioner would need to
hold state authority to obtain his initial
registration and any subsequent renewal
of the registration, but would not need
to hold state authority during the
intervening period between the granting
of his initial application and the
granting of his renewal application.
I reject Respondent’s contention and
adhere to the Agency’s longstanding and
consistent interpretation of the Act,
which has been affirmed by two courts
of appeals. See Hooper v. Holder, 481
Fed. Appx. at 828; Maynard v. DEA, 117
Fed. Appx. 941, 945 (5th Cir. 2004). As
the Fourth Circuit explained in Hooper,
in rejecting the practitioner’s contention
that the Agency’s revocation of his
registration ignored the discretion
granted by section 824 and read the
suspension option out of the statute:
We find Hooper’s contention
unconvincing. Section 824(a) does state that
the [Agency] may ‘‘suspend or revoke’’ a
registration, but the statute provides for this
sanction in five different circumstances, only
one of which is loss of a State license.
Because § 823(f) and § 802(21) make clear
that a practitioner’s registration is dependent
upon the practitioner having state authority
to dispense controlled substances, the
[Agency’s] decision to construe § 824(a)(3) as
mandating revocation upon suspension of a
state license is not an unreasonable
interpretation of the CSA. The [Agency’s]
decision does not ‘‘read[ ] the suspension
option’’ out of the statute, because that
option may still be available for the other
circumstances enumerated in § 824(a).
481 Fed. Appx., at 828. See also
Maynard, 117 Fed. Appx. at 945 (5th
Cir. 2004) (upholding revocation of DEA
registration after Texas DPS summarily
suspended practitioner’s controlled
substance registration, noting that the
Agency ‘‘has construed the CSA to
States, 130 S.Ct. 1345, 1354 (2010) (quoting D.
Ginsberg & Sons, Inc., v. Popkin, 285 U.S. 204, 208
(1932) (‘‘General language of a statutory provision,
although broad enough to include it, will not be
held to apply to a matter specifically dealt with in
another part of the same enactment.’’)).
E:\FR\FM\22NON1.SGM
22NON1
asabaliauskas on DSKBBXCHB2PROD with NOTICES
55638
Federal Register / Vol. 82, No. 224 / Wednesday, November 22, 2017 / Notices
require revocation when a registrant no
longer possesses valid state authority to
handle controlled substances’’; ‘‘We
agree with [the] argument that it may
have been arbitrary and capricious had
the DEA failed to revoke [the
physician’s] registration under the
circumstances.’’).
In his Reply to the Government’s
Motion, Respondent made an additional
argument beyond that made in Hooper.
He contended that ‘‘[it] is noteworthy
that [section] 824(a) . . . employs the
word ‘may’ in authorizing the Attorney
General to revoke or suspend a
registration, when among other factors,
the registrant is no longer authorized by
State law to engage in the dispensing of
controlled substances.’’ Resp. Reply, at
6. In Respondent’s view, ‘‘under
[section] 824(a), the loss of state
authority is only one of several factors
that may result in suspension or
revocation of a practitioner’s DEA
registration.’’ Id. He maintained that
‘‘[t]he correct interpretation is that
[section] 802(21) and [section] 823(f)
require state authority in order for the
Administrator to grant an application
for registration, but [section] 824(a)(3)
only renders a loss of state authority a
discretionary factor in determining
whether to suspend or revoke an
existing registration.’’ Id. Based on his
view that the loss of state authority is
simply a discretionary factor,
Respondent suggests that the use of
summary disposition to resolve this
matter is improper. Id.
Respondent, however, cites no
authority for his contention that the
various grounds set forth in section
824(a) pursuant to which the Agency is
authorized to suspend or revoke a
registration are merely ‘‘discretionary
factors’’ in the same manner as are the
public interest factors of section 823.
Indeed, his argument is refuted by the
texts of section 823(f) and 824(a) and the
history of the CSA.
Notably, section 823(f) instructs that
‘‘[i]n determining the public interest,
the following factors shall be
considered’’ and then lists the five
factors. 21 U.S.C. 823(f). By contrast,
section 824(a) makes no reference to
‘‘factors.’’ Rather, the provision begins
with the word ‘‘Grounds’’ and then
states that ‘‘[a] registration pursuant to
section 823 of this title . . . may be
suspended or revoked by the Attorney
General upon a finding that’’ one of the
five different grounds apply to the
registrant.7 Id. § 824(a).
7 As noted above, Respondent invokes the canon
of statutory construction that ‘‘[w]here Congress
includes particular language in one section of a
statute but omits it in another . . . , it is generally
VerDate Sep<11>2014
18:57 Nov 21, 2017
Jkt 244001
Had Congress intended that the
various findings set forth in section
824(a) be treated as ‘‘discretionary
factors,’’ it would have done so by using
language similar to that it used in
section 823(f). See Jama v. ICE, 543 U.S.
335, 341 (2005) (‘‘We do not lightly
assume that Congress has omitted from
its adopted text requirements that it
nonetheless intends to apply, and our
reluctance is even greater when
Congress has shown elsewhere in the
same statute that it knows how to make
such a requirement manifest.’’).
Rather, the findings enumerated in
section 824(a) are grants of authority,
each of which provides an independent
and adequate ground to impose a
sanction on a registrant. See Alfred S.
Santucci, 67 FR 68688 (2002) (‘‘Loss of
state authority is an independent
ground to revoke a practitioner’s
registration under 21 U.S.C. 824(a)(3).’’);
VI Pharmacy, Rushdi Z. Salem, 69 FR
5584, 5585 (2004) (‘‘Pursuant to 21
U.S.C. 824(a)(1), falsification of a DEA
application constitutes independent
grounds to revoke a registration.’’);
Lazaro Guerra, 68 FR 15226, 15227
(2003) (‘‘mandatory exclusion from
participation in the Medicare program
pursuant to 42 U.S.C. 1320a–7(a) . . . is
an independent ground for revoking a
DEA registration’’ (citing 21 U.S.C.
824(a)(5)). See also Richard B. Lynch,
Jr., 50 FR 7844, 7845 (1985) (Agency
made findings under section 824(a)(1),
824(a)(2), and 824(a)(3); ‘‘The
Administrator concludes that there are
three independent statutory grounds for
denial of the subject application.’’).
The Agency’s interpretation is
buttressed by the CSA’s legislative
history. As originally enacted, the CSA
granted the Attorney General authority
to suspend or revoke a registration:
Upon a finding that the registrant—
(1) has materially falsified any application
filed pursuant to or required by this title [the
CSA] or title III [the Controlled Substance
Import Export Act (CSIEA), 21 U.S.C. 951–
971];
(2) has been convicted of a felony under
[the CSA or CSIEA] or any other law of the
United States, or of any State, relating to any
substance defined in this title as a controlled
substance; or
presumed that Congress acts intentionally and
purposely in the disparate inclusion or exclusion’’;
he argues that it is significant that while Congress
used the word ‘‘practitioner’’ in section 823, it used
the word ‘‘registrant’’ in section 824(a). Resp.’s
Reply, at 5 & n.14 (quoting Keene Corp., 508 U.S.
at 208 (other citation omitted)). Contrary to
Respondent’s contention, the correct comparison is
between the language of section 823(f), which states
that ‘‘[i]n determining the public interest, the
following factors shall be considered,’’ and the
language of section 824(a), which authorizes the
Agency to suspend or revoke a registration upon
making one of the five enumerated ‘‘finding[s].’’
PO 00000
Frm 00086
Fmt 4703
Sfmt 4703
(3) has had his state license or registration
suspended, revoked, or denied by competent
state authority and is no longer authorized by
State law to engage in the . . . dispensing of
controlled substances.
Public Law 91–513, § 304, 84 Stat.
1255 (codified at 21 U.S.C. 824(a)).8
Describing this provision, the House
Report explained that ‘‘[s]ubsection (a)
of this section empowers the Attorney
General to revoke or suspend any
registration issued under this title if it
is found that the holder has falsified his
application, lost his State license, or has
been convicted of a felony violation
relating to any controlled substance.’’ H.
Rep. No. 91–1444 (1970), as reprinted in
1970 U.S.C.C.A.N. 4566, 4608–09.
Absent from this statement is any
discussion that in determining the
sanction, the Attorney General was
required to consider not only whether a
registrant had lost his state authority,
but also whether he had also materially
falsified his application or had been
convicted of a felony related to a
controlled substance.
Moreover, while in 1984, Congress
amended the CSA by granting the
Attorney General authority to deny an
application for a practitioner’s
registration and to revoke an existing
registration on public interest grounds,
it did so to increase the Agency’s
authority to respond to the ‘‘[i]mproper
diversion of controlled substances by
practitioners,’’ which Congress
explained ‘‘is one of the most serious
aspects of the drug abuse problem.’’ H.
Rep. No. 98–1030, at 266 (1984), as
reprinted in 1984 U.S.C.C.A.N. 3182,
3448. The House Report explained that
‘‘effective Federal actions against
practitioners has been severely inhibited
by the limited authority in current law
to deny or revoke practitioner
registrations’’ and that ‘‘the current
limited grounds for revoking or denying
a practitioner’s registration have been
cited as contributing to the problem of
diversion of dangerous drugs.’’ Id.
Finding that ‘‘the overly limited bases in
current law for denial or revocation of
a practitioner’s registration do not
operate in the public interest,’’ Congress
amended section 823(f) ‘‘to expand the
authority of the Attorney General to
deny a practitioner’s registration
application’’ based upon a finding ‘‘that
registration would be ‘inconsistent with
the public interest.’’’ Id. (emphasis
added).
8 Cf. Reiter v. Sonotone Corp., 442 U.S.C. 330, 339
(1979) (‘‘Canons of construction ordinarily suggest
that terms connected by a disjunctive be given
separate meanings, unless the context dictates
otherwise[.]’’) (citing FCC v. Pacifica Foundation,
438 U.S. 726, 739–40 (1978)).
E:\FR\FM\22NON1.SGM
22NON1
55639
Federal Register / Vol. 82, No. 224 / Wednesday, November 22, 2017 / Notices
While Congress also amended section
‘‘824(a) to add to the current bases for
denial, revocation, or suspension of
registration a finding that registration
would be inconsistent with the public
interest on the grounds specified in
[section] 823, which will include
consideration of the new factors added
by’’ the amendment, id. at 266–67,
Congress did not otherwise alter the text
of section 824(a), which makes clear
that the various paragraphs of this
provision are findings, each of which
provides an independent and adequate
ground to support agency action against
a registration, and not discretionary
factors to be considered by the Agency.
Indeed, Respondent points to nothing in
the language of section 824 or the CSA’s
legislative history to support his
position, which would fundamentally
alter the scope of the Agency’s authority
under section 824.
I therefore reject Respondent’s
contentions. Based on the ALJ’s finding
that Respondent is not currently
authorized to dispense controlled
substances in Mississippi, the State in
which he holds the DEA registration at
issue in this proceeding, I will adopt the
ALJ’s recommended order that I revoke
his registration.
DEPARTMENT OF JUSTICE
Order
ACTION:
Pursuant to the authority vested in me
by 21 U.S.C. 824(a), as well as 28 CFR
0.100(b), I order that DEA Certificate of
Registration No. AF2451261 issued to
Arnold E. Feldman, M.D., be, and it
hereby is, revoked. This Order is
effective immediately.9
SUMMARY:
Dated: November 13, 2017.
Robert W. Patterson,
Acting Administrator.
[FR Doc. 2017–25287 Filed 11–21–17; 8:45 am]
BILLING CODE 4410–09–P
Drug Enforcement Administration
[Docket No. DEA–392]
Importer of Controlled Substances
Registration
Registrants listed below have
applied for and been granted
registration by the Drug Enforcement
Administration as importers of various
classes of schedule I or II controlled
substances.
The
companies listed below applied to be
registered as importers of various basic
classes of controlled substances.
Information on previously published
notices is listed in the table below. No
comments or objections were submitted
and no requests for hearing were
submitted for these notices.
SUPPLEMENTARY INFORMATION:
Company
FR Docket
asabaliauskas on DSKBBXCHB2PROD with NOTICES
Almac Clinical Services Incorp (ACSI) ........................................................................................................
Stepan Company .........................................................................................................................................
Fresenius Kabi USA, LLC ...........................................................................................................................
Cambrex Charles City .................................................................................................................................
Spex Certiprep Group, LLC .........................................................................................................................
Akorn, Inc ....................................................................................................................................................
Fisher Clinical Services, Inc ........................................................................................................................
Siegfried USA, LLC .....................................................................................................................................
Mylan Pharmaceuticals, Inc ........................................................................................................................
KVK-Tech, Inc .............................................................................................................................................
Cerilliant Corporation ...................................................................................................................................
Unither Manufacturing LLC .........................................................................................................................
Mylan Pharmaceuticals, Inc ........................................................................................................................
Catalent Centers, LLC .................................................................................................................................
Specgx LLC .................................................................................................................................................
Sharp Clinical Services, Inc ........................................................................................................................
Cody Laboratories, Inc ................................................................................................................................
Bellwyck Clinical Services ...........................................................................................................................
The Drug Enforcement
Administration (DEA) has considered
the factors in 21 U.S.C. 823, 952(a) and
958(a) and determined that the
registration of the listed registrants to
import the applicable basic classes of
schedule I or II controlled substances is
consistent with the public interest and
with United States obligations under
international treaties, conventions, or
protocols in effect on May 1, 1971. The
DEA investigated each company’s
maintenance of effective controls
against diversion by inspecting and
testing each company’s physical
9 While the Mississippi Board Order was based on
the Louisiana Board’s Order, as noted in the former
Acting Administrator’s Decision and Order which
revoked Respondent’s Louisiana registration, the
Louisiana Board found proved the sixth charge of
the Administrative Complaint in that proceeding, in
VerDate Sep<11>2014
18:57 Nov 21, 2017
Jkt 244001
Notice of registration.
security systems, verifying each
company’s compliance with state and
local laws, and reviewing each
company’s background and history.
Therefore, pursuant to 21 U.S.C.
952(a) and 958(a), and in accordance
with 21 CFR 1301.34, the DEA has
granted a registration as an importer for
schedule I or II controlled substances to
the above listed persons.
82
82
82
82
82
82
82
82
82
82
82
82
82
82
82
82
82
82
FR
FR
FR
FR
FR
FR
FR
FR
FR
FR
FR
FR
FR
FR
FR
FR
FR
FR
37114
41054
41053
41055
42120
42117
42121
42117
42120
42119
43404
43571
43572
43569
43571
43572
45612
45613
Published
August 8, 2017.
August 29, 2017.
August 29, 2017.
August 29, 2017.
September 6, 2017.
September 6, 2017.
September 6, 2017.
September 6, 2017.
September 6, 2017.
September 6, 2017.
September 15, 2017.
September 18, 2017.
September 18, 2017.
September 18, 2017.
September 18, 2017.
September 18, 2017.
September 29, 2017.
September 29, 2017.
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Linda M. Shuck, D.O.; Decision and
Order
BILLING CODE 4410–09–P
On July 25, 2017, the Assistant
Administrator, Diversion Control
Division, Drug Enforcement
Administration, issued an Order to
Show Cause to Linda M. Shuck
(Registrant), of Dobson, North Carolina.
The Show Cause Order proposed the
revocation of Registrant’s Certificate of
Registration, on the ground that she
that Respondent violated state law by
‘‘[p]rescribing, dispensing, or administering legally
controlled substances or any dependency-inducing
medication without legitimate medical justification
thereof or in other than a legal or legitimate
manner.’’ See 82 FR at 39618 n.8 (2017); see also
Mot. for Summ. Disp., Appendix B, at 22, 24
(Louisiana Board Order at 12, 14). For the same
reasons as those cited by the former Acting
Administrator, I find that the public interest
necessitates that this Order be effective
immediately. See also 21 CFR 1316.67.
Dated: November 16, 2017.
Demetra Ashley,
Acting Assistant Administrator.
[FR Doc. 2017–25284 Filed 11–21–17; 8:45 am]
PO 00000
Frm 00087
Fmt 4703
Sfmt 4703
E:\FR\FM\22NON1.SGM
22NON1
Agencies
[Federal Register Volume 82, Number 224 (Wednesday, November 22, 2017)]
[Notices]
[Pages 55635-55639]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-25287]
[[Page 55635]]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. 17-34]
Arnold E. Feldman, M.D.; Decision and Order
On May 24, 2017, the Assistant Administrator, Diversion Control
Division, issued an Order to Show Cause to Arnold E. Feldman, M.D.
(Respondent), of Natchez, Mississippi. The Show Cause Order proposed
the revocation of Respondent's DEA Certificate of Registration No.
AF2451261, on the ground that he ``do[es] not have authority to handle
controlled substances in the State of Mississippi, the [S]tate in which
[he is] registered with . . . DEA.'' Show Cause Order, at 1.
As to the jurisdictional basis for the proceeding, the Show Cause
Order alleged that Respondent is ``registered as a practitioner in
[s]chedules II-V pursuant to [Registration No.] AF2451261 with a
registered address at 114 Jefferson Davis [Blvd.], Natchez,
Mississippi.'' Id. The Order also alleged that this registration does
not expire until ``September 30, 2018.'' Id.
As to the substantive ground for the proceeding, the Show Cause
Order alleged that Respondent's ``[a]uthority to prescribe and
administer controlled substances in the State of Mississippi was
suspended effective March 16, 2017.'' Id. The Order then asserted that
as a consequence of Respondent's ``lack of authority to handle
controlled substances in the State of Mississippi,'' his registration
is subject to revocation. Id.
The Show Cause Order notified Respondent of his right to request a
hearing on the allegation or to submit a written statement while
waiving his right to a hearing and the procedure for electing either
option. Id. at 2 (citing 21 CFR 1301.43). In addition, the Order
notified Respondent of his right to submit a corrective action plan
pursuant to 21 U.S.C. 824(c)(2)(C). Id. at 2-3.
On June 15, 2017, Respondent, through his counsel, requested a
hearing on the allegation. Letter from Respondent's Counsel to Hearing
Clerk, Office of Administrative Law Judges (June 15, 2017). The same
day, the matter was assigned to Administrative Law Judge Charles Wm.
Dorman (hereinafter, ALJ), who issued an order (also on June 15)
directing the Government to file evidence supporting the allegation by
June 28, 2017 at 2 p.m., as well any motion for summary disposition.
Briefing Schedule For Lack Of State Authority Allegations, at 1. The
ALJ's order also provided that if the Government moved for summary
disposition, Respondent's opposition was due by July 12, 2017 at 2 p.m.
Id.
On June 20, 2017, the Government filed its Motion for Summary
Disposition. As support for its motion, the Government provided, inter
alia: (1) A copy of Respondent's registration; (2) the Determination of
the Mississippi State Board of Medical Licensure (Mar. 16, 2017) which
ordered the suspension of his medical license ``to run concurrently''
with the suspension of his Louisiana medical license that was imposed
by the Louisiana Board of Medical Examiners' Order of August 15, 2016;
\1\ and (3) a Declaration of a Diversion Investigator. Mot. for Summ.
Disp., Appendices A, B, C. In its motion, the Government argued that it
was undisputed that Respondent's Mississippi medical license is
suspended and that because ``Respondent no longer meets the statutory
definition of a practitioner'' and ``possession of authority to
dispense controlled substances under the laws of the State in which a
practitioner engages in professional practice is a fundamental
condition for both obtaining and maintaining a practitioner's
registration,'' the revocation of Respondent's registration for his
Mississippi office is warranted. Mot. for Summ. Disp., at 3-4.
---------------------------------------------------------------------------
\1\ The Government also included various other documents from
the Mississippi Board proceeding, including an Order of Continuance,
an Order of Temporary Action Pending Hearing, a Summons issued to
Respondent, an Affidavit of a Board Investigator, and a copy of the
Louisiana Board's Decision and Order which was an exhibit in the
Mississippi Board proceeding. See generally Mot. for Summ. Disp., at
Appendix B. Based on the suspension of his Louisiana medical
license, on August 14, 2017, the former Acting Administration
revoked Respondent's DEA registration for his practice in Baton
Rouge, Louisiana. See Arnold E. Feldman, 82 FR 39614, 39618 (2017).
---------------------------------------------------------------------------
On July 10, 2017, Respondent filed his Reply to the Government's
Motion. Therein, ``Respondent acknowledge[d] that his license to
practice medicine in . . . Mississippi has been suspended in accordance
with the . . . Mississippi State Board of Medical Licensure's Order.''
Resp. Reply, at 1. Respondent contended, however, ``that there are
material questions of fact and law that require resolution in a
plenary, evidentiary proceeding.'' Id.
According to Respondent, these issues are that he possesses ``an
active and unrestricted license to practice medicine in'' Alabama and
``a full and unrestricted Alabama Controlled Substance Certificate.''
Id. at 2. Respondent argued that ``none of the cases cited by the
Government'' address the situation ``where a physician has lost
authority to practice in one state, while retaining unrestricted
authority in another.'' Id. at 3. He also argued that the Agency's
longstanding rule that a practitioner must possess authority under the
laws of the State in which he engages in professional practice ``is
based on the indiscriminate intermingling of'' 21 U.S.C. 823 and 824,
``each of which deals with different aspects of the control and
enforcement authority to dispense controlled substances.'' Id. He
further contended that while section 823 mandates that the Attorney
General ``register the applicant'' if he ``is authorized to dispense
controlled substances under the laws of the State in which he
practices,'' ``[t]he term `practitioner' does not appear in'' section
824 and the latter provision ``does not speak to a physician's
authorization to practice or dispense under the laws of the state in
which the registrant practices.'' Id. at 4.
In Respondent's view, section 824 authorizes revocation ``only if
the registrant is no longer authorized by State law to engage in the
dispensing of controlled substances [under] any state law.'' Id. at 5.
He also maintained that ``[t]he fact that Congress employed the term
`practitioner' in'' section 823(f) but not in section 824 ``is a clear
indication that it did not intend to authorize revocation or suspension
of a [registration] where a registrant has continued to maintain
authority to practice and dispense under the laws of any state.'' Id.;
see also id. at 5 & n.14 (``Where Congress includes particular language
in one section of a statute but omits it in another . . . it is
generally presumed that Congress acts intentionally and purposely in
the disparate inclusion or exclusion.'') (quoting Keene Corp. v United
States, 508 U.S. 200, 208 (1993) (other citation omitted)).
Finally, Respondent contended that ``[t]he Government, and the
cases cited by it, indiscriminately (and erroneously) intermingle''
sections 823 and 824, and this intermingling along with ``its
misinterpretation of 21 U.S.C. 824(a)(3) amount to a violation of [his]
constitutional right to travel.'' Id. at 6-7. He argued that
``[t]heoretically, [he] should be able to pack up and remove himself
and his practice from Louisiana to . . . Alabama, where he is
authorized to practice medicine and dispense controlled substances.
But[] his constitutional right to do so is impaired by the Government's
misinterpretation of its authority to revoke'' his registration. Id. at
7.
On July 25, 2017, the ALJ granted the Government's Motion. The ALJ
found
[[Page 55636]]
that ``Respondent conceded in his Reply that his Mississippi medical
license is currently suspended'' and that ``it is undisputed that . . .
Respondent lacks state authorization to handle controlled substances in
Mississippi, where [his Registration] Number AF2451261[] is
registered.'' ALJ's Recommended Decision (R.D.), at 6. Because
Respondent is registered in Mississippi, the ALJ found it irrelevant
that Respondent holds a license to practice medicine in Alabama. Id. at
4 (citing cases). The ALJ noted that ``both the CSA's `definition of
the term ``practitioner'' and the registration provision applicable to
practitioners make clear that a practitioner must be currently
authorized to dispense controlled substances by the State in which he
practices in order to obtain and maintain a registration,''' and that
the Agency's interpretation has been upheld by the Fourth Circuit. Id.
(quoting Rezik A. Saqer, 81 FR 22122, 22125 (2016) and citing Hooper v.
Holder, 481 Fed. App'x 826 (4th Cir. 2012)). The ALJ further reasoned
that ``Respondent's analysis is counter to the way the DEA has
interpreted the CSA for nearly forty years.'' Id. at 5 (citing Saqer,
81 FR at 22126 (citing Frederick Marsh Blanton, 43 FR 27616 (1978))).
The ALJ also rejected Respondent's contention that the Agency's
interpretation impairs his constitutional right to travel. Id. at 5-6.
The ALJ noted that under DEA's regulation, `` `[a] separate
registration is required for each principal place of business.' '' Id.
at 5 (quoting 21 CFR 1301.12(a)). The ALJ also noted that in 2006, the
Agency issued a final rule which ``clarif[ied] that a practitioner must
obtain a separate DEA registration for each [S]tate in which he or she
practices,'' and that `` `[j]ust as a license to practice medicine in
one State does not authorize a practitioner to practice in any other
State, a DEA registration based on a particular State's license cannot
authorize dispensing controlled substances in another State.' '' Id. at
6 (quoting Clarification of Registration Requirements for Individual
Practitioners, 71 FR 69478, 69479 (2006) and citing Joe W. Morgan, 78
FR 61961, 61965 n.13 (2013)). The ALJ thus explained that ``Respondent
is able to pack up and remove himself and his practice from
[Mississippi] to Alabama--he just cannot dispense or prescribe
controlled substances there unless he first obtains a separate DEA
registration for his Alabama location in accordance with 21 CFR
1301.12(a).'' Id. The ALJ thus recommended that I revoke Respondent's
registration. Id. at 7.
Neither party filed Exceptions to the ALJ's Recommended Decision.
Thereafter, on August 22, 2017, the ALJ forwarded the record to me for
Final Agency Action.\2\
---------------------------------------------------------------------------
\2\ Subsequent to the ALJ's issuance of his Recommended Order,
Respondent has not filed a motion based on newly discovered evidence
to the effect that his state licensed has been restored.
---------------------------------------------------------------------------
Having considered the record, I reject Respondent's various
contentions and adopt the ALJ's Recommended Decision. I will therefore
also adopt the ALJ's recommendation that I revoke Respondent's
registration. I make the following findings.
Findings of Fact
Respondent is the holder of DEA Certificate of Registration No.
AF2451261, pursuant to which he is authorized to dispense controlled
substances in schedules II through V as a practitioner, at the
registered address of: Southwest MS Anesthesia PA, 114 Jefferson Davis
Blvd., Natchez, Mississippi. Mot. for Summ. Disp., Appendix A. This
registration does not expire until September 30, 2018. Id.
Respondent also holds a medical license issued by the Mississippi
State Board of Medical Licensure. See Mot. for Summ. Disp., Appendix B,
Determination and Order, at 2. However, on March 16, 2017, the Board
issued a Determination and Order which suspended his medical license
for a period ``to run concurrently with'' the suspension of his
Louisiana medical license, ``that is, until October 14, 2018, at which
time [he] shall petition the Board for removal of the suspension''; the
Mississippi Board's Order was effective on April 17, 2017. Id. at 4.
Accordingly, I find that Respondent currently lacks authority to
dispense controlled substances under the laws of the State of
Mississippi.
Discussion
Pursuant to 21 U.S.C. 824(a)(3), the Attorney General is authorized
to suspend or revoke a registration issued under section 823 of the
Controlled Substances Act (CSA), ``upon a finding that the registrant .
. . has had his State license . . . suspended [or] revoked . . . by
competent State authority and is no longer authorized by State law to
engage in the . . . dispensing of controlled substances.'' With respect
to a practitioner, DEA has long held that the possession of authority
to dispense controlled substances under the laws of the State in which
a practitioner engages in professional practice is a fundamental
condition for obtaining and maintaining a practitioner's registration.
See, e.g., James L. Hooper, 76 FR 71371 (2011), pet. for rev. denied,
481 Fed. Appx. 826 (4th Cir. 2012); Frederick Marsh Blanton, 43 FR
27616 (1978).
Respondent acknowledges that the Agency's precedents ``do indeed
reveal a consistent [and in his view] uncritical repetition of th[is]
claim, to an extent . . . that the proposition has come to attain near
sacrosanct status.'' Resp. Reply, at 3. Before the ALJ, he contended
that the Agency's rule ``is based on the indiscriminate intermingling
of'' the registration requirements of section 823 and the suspension/
revocation authority of section 824. Id. He also argued that because
``the term `practitioner' is employed solely in 21 U.S.C. 823'' and
``does not appear in section 824'' this ``is a clear indication that
[Congress] did not intend to authorize an automatic, summary revocation
. . . where a registrant has continued to maintain authority to
practice and dispense under the laws of any state.'' Id. at 4.
Respondent is mistaken. As the Agency has repeatedly noted, the
Agency's rule actually derives from the text of section 802(21), which
defines the term ``practitioner,'' and section 823(f), which sets forth
the requirements for obtaining a practitioner's registration. Notably,
in section 802(21), Congress defined ``the term `practitioner' [to]
mean[ ] a . . . physician . . . or other person licensed, registered or
otherwise permitted, by . . . the jurisdiction in which he practices .
. . to distribute, dispense, [or] administer . . . a controlled
substance in the course of professional practice.'' 21 U.S.C. 802(21).
The text of this provision makes clear that a physician is not a
practitioner within the meaning of the CSA if he is not ``licensed,
registered or otherwise permitted, by the jurisdiction in which he
practices . . . to dispense [or] administer . . . a controlled
substance in the course of professional practice.'' Id.
To the same effect, Congress, in setting the requirements for
obtaining a practitioner's registration, directed that ``[t]he Attorney
General shall register practitioners . . . if the applicant is
authorized to dispense . . . controlled substances under the laws of
the State in which he practices.'' 21 U.S.C. 823(f). Thus, based on
these provisions, the Agency held nearly 40 years ago that ``[s]tate
authorization to dispense or otherwise handle controlled substances is
a prerequisite to the issuance and maintenance of a Federal controlled
substances registration.'' Blanton, 43 FR
[[Page 55637]]
at 27617 (revoking physician's registration based on one-year
suspension of his state license) (emphasis added).
As the ALJ recognized, the CSA also provides that ``[a] separate
registration shall be required at each principal place of business or
professional practice where the applicant . . . dispenses controlled
substances.'' 21 U.S.C. 822(e).\3\ Based on this provision, the Agency
has further explained that, because the issuance of a registration is
dependent on a practitioner having authority to dispense controlled
substances under the laws of a particular State, a registration issued
for a location in one State cannot authorize the practitioner to engage
in controlled substance dispensing in another State. See Clarification
of Registration Requirements for Individual Practitioners, 71 FR 69478
(2006); 21 CFR 1301.12(a) & (b)(3). See also United States v. Moore,
423 U.S. 122, 140-41 (1975) (``Registration of physicians and other
practitioners is mandatory if the applicant is authorized to dispense
drugs . . . under the law of the State in which he practices. [21
U.S.C. ] Sec. 823(f). In the case of a physician, this scheme
contemplates that he is authorized by the State to practice medicine
and to dispense drugs in connection with his professional
practice.'').\4\
---------------------------------------------------------------------------
\3\ See also 21 U.S.C. 822(b) (``Persons registered by the
Attorney General . . . to . . . dispense controlled substances . . .
are authorized to possess . . . or dispense such substances . . . to
the extent authorized by their registration and in conformity with
the other provisions of this subchapter.'').
\4\ While the CSA was amended in 1984 to provide the Agency with
authority to deny a practitioner's registration on public interest
grounds, the requirement that a practitioner be ``authorized to
dispense . . . controlled substances under the laws of the State in
which he practices,'' 21 U.S.C. 823(f), was unaltered by this
legislation.
---------------------------------------------------------------------------
Notably, while Respondent holds a medical license in Alabama, the
registration at issue in this proceeding authorizes him to dispense
controlled substances only in the State of Mississippi. Moreover, the
Show Cause Order proposes only the revocation of this registration.\5\
Because Congress has clearly mandated that a practitioner possess state
authority in order to be deemed a practitioner under the Act, and
Respondent is no longer authorized to dispense controlled substances
under the laws of Mississippi, the State of the registration at issue
here, revocation of this registration is the appropriate sanction. See,
e.g., Hooper, 76 FR at 71371-72; Sheran Arden Yeates, 71 FR 39130,
39131 (2006); Dominick A. Ricci, 58 FR 51104, 51105 (1993); Bobby
Watts, 53 FR 11919, 11920 (1988); Blanton, 43 FR at 27616.
---------------------------------------------------------------------------
\5\ There is no evidence in the record as to whether Respondent
holds a DEA registration in Alabama. Nor does this matter, because
the Government proposes only the revocation of his Mississippi
registration.
---------------------------------------------------------------------------
As noted above, Respondent contends that Congress' use of the word
``registrant'' rather the word ``practitioner'' in section 824 ``is a
clear indication that it did not intend to authorize an automatic
revocation of a [registration] where a registrant has continued to
maintain authority to practice and dispense under the laws of any
state.'' Resp. Reply, at 5. A practitioner is, however, a particular
category of registrant and thus falls within section 824(a). Given the
provisions of section 802(21) and 823(f), it is not clear why Congress
needed to use the word ``practitioner'' in section 824(a) to authorize
the Agency to effectuate the policy expressed by sections 802(21) and
823(f). Moreover, Respondent ignores that there is a good reason for
why Congress used different language in sections 823(f) and 824(a) to
describe the class of persons who are subject to each provision, and
this reason provides no support for Respondent's contention.
Section 823(f) is specifically applicable to those applicants
seeking registration as a practitioner, which is just one of eight
different categories of registration under the CSA. See generally 21
U.S.C. 823. By contrast, section 824(a), which authorizes the
imposition of sanctions against a registrant based on any one of five
findings, is applicable to all categories of registrants under the CSA,
including Respondent. See, e.g., James L. Hooper, 76 FR 71371 (2011),
pet. for rev. denied Hooper v. Holder, 481 Fed. Appx. 826, 829 (4th
Cir. 2012).
As explained above, the Agency's rule that revocation is warranted
whenever a practitioner is no longer authorized to dispense controlled
substances under the laws of the State in which he engages in
professional practice is derived from the specific provisions of the
Act which define the term ``practitioner'' and set forth the
registration requirements which are specifically applicable to
practitioners.\6\ Hooper, 76 FR at 71371-72. Indeed, were I to adopt
Respondent's view, he would be allowed to maintain his registration
even though his lack of state authority bars him from obtaining a
registration in Mississippi in the first place. 21 U.S.C. 823(f).
---------------------------------------------------------------------------
\6\ Section 824(a)(3) grants authority applicable to all
categories of DEA registrants (and not only practitioners) as well
as each of the enumerated findings. As explained in Hooper, this
general grant of authority in imposing a sanction must be reconciled
with the CSA's specific provisions which mandate that a practitioner
hold authority under state law in order to obtain and maintain a DEA
registration. 76 FR, at 71371-72 (quoting Gozlon-Peretz v. United
States, 498 U.S. 395, 407 (1991) (``A specific provision controls
over one of more general application.'') and Bloate v. United
States, 130 S.Ct. 1345, 1354 (2010) (quoting D. Ginsberg & Sons,
Inc., v. Popkin, 285 U.S. 204, 208 (1932) (``General language of a
statutory provision, although broad enough to include it, will not
be held to apply to a matter specifically dealt with in another part
of the same enactment.'')).
---------------------------------------------------------------------------
Moreover, under DEA regulations, a practitioner's registration is
good for a period of three years, after which a practitioner must
submit a renewal application. Yet that renewal application remains
subject to section 823(f), which requires that ``the applicant is
authorized to dispense . . . controlled substances under the laws of
the State in which he practices.'' Respondent's view leads to the
illogical result that a practitioner would need to hold state authority
to obtain his initial registration and any subsequent renewal of the
registration, but would not need to hold state authority during the
intervening period between the granting of his initial application and
the granting of his renewal application.
I reject Respondent's contention and adhere to the Agency's
longstanding and consistent interpretation of the Act, which has been
affirmed by two courts of appeals. See Hooper v. Holder, 481 Fed. Appx.
at 828; Maynard v. DEA, 117 Fed. Appx. 941, 945 (5th Cir. 2004). As the
Fourth Circuit explained in Hooper, in rejecting the practitioner's
contention that the Agency's revocation of his registration ignored the
discretion granted by section 824 and read the suspension option out of
the statute:
We find Hooper's contention unconvincing. Section 824(a) does
state that the [Agency] may ``suspend or revoke'' a registration,
but the statute provides for this sanction in five different
circumstances, only one of which is loss of a State license. Because
Sec. 823(f) and Sec. 802(21) make clear that a practitioner's
registration is dependent upon the practitioner having state
authority to dispense controlled substances, the [Agency's] decision
to construe Sec. 824(a)(3) as mandating revocation upon suspension
of a state license is not an unreasonable interpretation of the CSA.
The [Agency's] decision does not ``read[ ] the suspension option''
out of the statute, because that option may still be available for
the other circumstances enumerated in Sec. 824(a).
481 Fed. Appx., at 828. See also Maynard, 117 Fed. Appx. at 945 (5th
Cir. 2004) (upholding revocation of DEA registration after Texas DPS
summarily suspended practitioner's controlled substance registration,
noting that the Agency ``has construed the CSA to
[[Page 55638]]
require revocation when a registrant no longer possesses valid state
authority to handle controlled substances''; ``We agree with [the]
argument that it may have been arbitrary and capricious had the DEA
failed to revoke [the physician's] registration under the
circumstances.'').
In his Reply to the Government's Motion, Respondent made an
additional argument beyond that made in Hooper. He contended that
``[it] is noteworthy that [section] 824(a) . . . employs the word `may'
in authorizing the Attorney General to revoke or suspend a
registration, when among other factors, the registrant is no longer
authorized by State law to engage in the dispensing of controlled
substances.'' Resp. Reply, at 6. In Respondent's view, ``under
[section] 824(a), the loss of state authority is only one of several
factors that may result in suspension or revocation of a practitioner's
DEA registration.'' Id. He maintained that ``[t]he correct
interpretation is that [section] 802(21) and [section] 823(f) require
state authority in order for the Administrator to grant an application
for registration, but [section] 824(a)(3) only renders a loss of state
authority a discretionary factor in determining whether to suspend or
revoke an existing registration.'' Id. Based on his view that the loss
of state authority is simply a discretionary factor, Respondent
suggests that the use of summary disposition to resolve this matter is
improper. Id.
Respondent, however, cites no authority for his contention that the
various grounds set forth in section 824(a) pursuant to which the
Agency is authorized to suspend or revoke a registration are merely
``discretionary factors'' in the same manner as are the public interest
factors of section 823. Indeed, his argument is refuted by the texts of
section 823(f) and 824(a) and the history of the CSA.
Notably, section 823(f) instructs that ``[i]n determining the
public interest, the following factors shall be considered'' and then
lists the five factors. 21 U.S.C. 823(f). By contrast, section 824(a)
makes no reference to ``factors.'' Rather, the provision begins with
the word ``Grounds'' and then states that ``[a] registration pursuant
to section 823 of this title . . . may be suspended or revoked by the
Attorney General upon a finding that'' one of the five different
grounds apply to the registrant.\7\ Id. Sec. 824(a).
---------------------------------------------------------------------------
\7\ As noted above, Respondent invokes the canon of statutory
construction that ``[w]here Congress includes particular language in
one section of a statute but omits it in another . . . , it is
generally presumed that Congress acts intentionally and purposely in
the disparate inclusion or exclusion''; he argues that it is
significant that while Congress used the word ``practitioner'' in
section 823, it used the word ``registrant'' in section 824(a).
Resp.'s Reply, at 5 & n.14 (quoting Keene Corp., 508 U.S. at 208
(other citation omitted)). Contrary to Respondent's contention, the
correct comparison is between the language of section 823(f), which
states that ``[i]n determining the public interest, the following
factors shall be considered,'' and the language of section 824(a),
which authorizes the Agency to suspend or revoke a registration upon
making one of the five enumerated ``finding[s].''
---------------------------------------------------------------------------
Had Congress intended that the various findings set forth in
section 824(a) be treated as ``discretionary factors,'' it would have
done so by using language similar to that it used in section 823(f).
See Jama v. ICE, 543 U.S. 335, 341 (2005) (``We do not lightly assume
that Congress has omitted from its adopted text requirements that it
nonetheless intends to apply, and our reluctance is even greater when
Congress has shown elsewhere in the same statute that it knows how to
make such a requirement manifest.'').
Rather, the findings enumerated in section 824(a) are grants of
authority, each of which provides an independent and adequate ground to
impose a sanction on a registrant. See Alfred S. Santucci, 67 FR 68688
(2002) (``Loss of state authority is an independent ground to revoke a
practitioner's registration under 21 U.S.C. 824(a)(3).''); VI Pharmacy,
Rushdi Z. Salem, 69 FR 5584, 5585 (2004) (``Pursuant to 21 U.S.C.
824(a)(1), falsification of a DEA application constitutes independent
grounds to revoke a registration.''); Lazaro Guerra, 68 FR 15226, 15227
(2003) (``mandatory exclusion from participation in the Medicare
program pursuant to 42 U.S.C. 1320a-7(a) . . . is an independent ground
for revoking a DEA registration'' (citing 21 U.S.C. 824(a)(5)). See
also Richard B. Lynch, Jr., 50 FR 7844, 7845 (1985) (Agency made
findings under section 824(a)(1), 824(a)(2), and 824(a)(3); ``The
Administrator concludes that there are three independent statutory
grounds for denial of the subject application.'').
The Agency's interpretation is buttressed by the CSA's legislative
history. As originally enacted, the CSA granted the Attorney General
authority to suspend or revoke a registration:
Upon a finding that the registrant--
(1) has materially falsified any application filed pursuant to
or required by this title [the CSA] or title III [the Controlled
Substance Import Export Act (CSIEA), 21 U.S.C. 951-971];
(2) has been convicted of a felony under [the CSA or CSIEA] or
any other law of the United States, or of any State, relating to any
substance defined in this title as a controlled substance; or
(3) has had his state license or registration suspended,
revoked, or denied by competent state authority and is no longer
authorized by State law to engage in the . . . dispensing of
controlled substances.
Public Law 91-513, Sec. 304, 84 Stat. 1255 (codified at 21 U.S.C.
824(a)).\8\
---------------------------------------------------------------------------
\8\ Cf. Reiter v. Sonotone Corp., 442 U.S.C. 330, 339 (1979)
(``Canons of construction ordinarily suggest that terms connected by
a disjunctive be given separate meanings, unless the context
dictates otherwise[.]'') (citing FCC v. Pacifica Foundation, 438
U.S. 726, 739-40 (1978)).
---------------------------------------------------------------------------
Describing this provision, the House Report explained that
``[s]ubsection (a) of this section empowers the Attorney General to
revoke or suspend any registration issued under this title if it is
found that the holder has falsified his application, lost his State
license, or has been convicted of a felony violation relating to any
controlled substance.'' H. Rep. No. 91-1444 (1970), as reprinted in
1970 U.S.C.C.A.N. 4566, 4608-09. Absent from this statement is any
discussion that in determining the sanction, the Attorney General was
required to consider not only whether a registrant had lost his state
authority, but also whether he had also materially falsified his
application or had been convicted of a felony related to a controlled
substance.
Moreover, while in 1984, Congress amended the CSA by granting the
Attorney General authority to deny an application for a practitioner's
registration and to revoke an existing registration on public interest
grounds, it did so to increase the Agency's authority to respond to the
``[i]mproper diversion of controlled substances by practitioners,''
which Congress explained ``is one of the most serious aspects of the
drug abuse problem.'' H. Rep. No. 98-1030, at 266 (1984), as reprinted
in 1984 U.S.C.C.A.N. 3182, 3448. The House Report explained that
``effective Federal actions against practitioners has been severely
inhibited by the limited authority in current law to deny or revoke
practitioner registrations'' and that ``the current limited grounds for
revoking or denying a practitioner's registration have been cited as
contributing to the problem of diversion of dangerous drugs.'' Id.
Finding that ``the overly limited bases in current law for denial or
revocation of a practitioner's registration do not operate in the
public interest,'' Congress amended section 823(f) ``to expand the
authority of the Attorney General to deny a practitioner's registration
application'' based upon a finding ``that registration would be
`inconsistent with the public interest.''' Id. (emphasis added).
[[Page 55639]]
While Congress also amended section ``824(a) to add to the current
bases for denial, revocation, or suspension of registration a finding
that registration would be inconsistent with the public interest on the
grounds specified in [section] 823, which will include consideration of
the new factors added by'' the amendment, id. at 266-67, Congress did
not otherwise alter the text of section 824(a), which makes clear that
the various paragraphs of this provision are findings, each of which
provides an independent and adequate ground to support agency action
against a registration, and not discretionary factors to be considered
by the Agency. Indeed, Respondent points to nothing in the language of
section 824 or the CSA's legislative history to support his position,
which would fundamentally alter the scope of the Agency's authority
under section 824.
I therefore reject Respondent's contentions. Based on the ALJ's
finding that Respondent is not currently authorized to dispense
controlled substances in Mississippi, the State in which he holds the
DEA registration at issue in this proceeding, I will adopt the ALJ's
recommended order that I revoke his registration.
Order
Pursuant to the authority vested in me by 21 U.S.C. 824(a), as well
as 28 CFR 0.100(b), I order that DEA Certificate of Registration No.
AF2451261 issued to Arnold E. Feldman, M.D., be, and it hereby is,
revoked. This Order is effective immediately.\9\
---------------------------------------------------------------------------
\9\ While the Mississippi Board Order was based on the Louisiana
Board's Order, as noted in the former Acting Administrator's
Decision and Order which revoked Respondent's Louisiana
registration, the Louisiana Board found proved the sixth charge of
the Administrative Complaint in that proceeding, in that Respondent
violated state law by ``[p]rescribing, dispensing, or administering
legally controlled substances or any dependency-inducing medication
without legitimate medical justification thereof or in other than a
legal or legitimate manner.'' See 82 FR at 39618 n.8 (2017); see
also Mot. for Summ. Disp., Appendix B, at 22, 24 (Louisiana Board
Order at 12, 14). For the same reasons as those cited by the former
Acting Administrator, I find that the public interest necessitates
that this Order be effective immediately. See also 21 CFR 1316.67.
Dated: November 13, 2017.
Robert W. Patterson,
Acting Administrator.
[FR Doc. 2017-25287 Filed 11-21-17; 8:45 am]
BILLING CODE 4410-09-P